Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multinational Double-Blind, Randomised Phase IIb Cooperative Group Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo when Administered in Combination with Chemotherapy and/or Endocrine Therapy in Patients with Locally Recurrent or Metastatic Breast Cancer.

Next Previous
Trial Profile

A Multinational Double-Blind, Randomised Phase IIb Cooperative Group Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo when Administered in Combination with Chemotherapy and/or Endocrine Therapy in Patients with Locally Recurrent or Metastatic Breast Cancer.

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Nov 2015

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sorafenib (Primary) ; Docetaxel; Letrozole
  • Indications Adenocarcinoma; HER2 negative breast cancer
  • Focus Therapeutic Use
  • Acronyms SOR; TIES

    • Most Recent Events

    • 27 Sep 2011 Results presented at the 2011 European Multidisciplinary Cancer Congress.
    • 13 Sep 2011 Results will be presented as a late-breaking abstract at ECCO-ESMO 2011, according to a Bayer press release.
    • 07 Apr 2010 Planned initiation date (22 Nov 2007) added as reported by ISRCTN: Current Controlled Trials.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top